Document is current
Any future updates will be listed below
-
Authors
Pei, Shengfei
Yang, Li
Gao, Huixia
Liu, Yuzhen
Dai, Erhei
Feng, Fumin
Lu, Jianhua
-
Funding
Funding for this research was provided by:
Innovative Research Group Project of the National Natural Science Foundation of China (81670525)
The Medical Research Program of Hebei Province (20231696)
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 3 September 2024
First Online: 10 September 2024
Competing interests
: The authors declare no competing interests.
: Viral hepatitis is a Class B infectious disease under China’s Infectious Disease Prevention and Control Law, and each case reported by a medical institution is reported through the direct reporting system of the infectious disease network and requires epidemiological investigation and surveillance testing to further clarify the source of the virus and infection. Specimens are first tested by the laboratories of medical institutions, of which positive specimens are reviewed by disease prevention and control institutions and the results are fed back to the sending units. Therefore, this study received ethical approval from the China Center for Disease Control and Prevention. Since the disease under investigation, viral hepatitis, is a statutory infectious disease subject to national statutory monitoring each year, informed consent is not required. For confidentiality reasons, all viral hepatitis data were analyzed anonymously.
